Evaluating hepatitis b virus reactivation during solid tumor chemotherapy: Evidence to guide pretreatment hepatitis b screening and prophylaxis

Annals of Internal Medicine

Volumn 164, Issue 1, 2016, Pages 64-65

  Re, Vincent Lo ^a   Schuster, Mindy ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN;

ADVERSE OUTCOME; BREAST CANCER; CANCER CHEMOTHERAPY; DIGESTIVE SYSTEM CANCER; EDITORIAL; HEAD AND NECK CANCER; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION PREVENTION; INFECTION RISK; LUNG CANCER; PREMEDICATION; PRIORITY JOURNAL; RISK FACTOR; SOLID TUMOR; VIRUS REACTIVATION; HEPATITIS B, CHRONIC; NEOPLASMS; PHYSIOLOGY; VIROLOGY; VIRUS ACTIVATION;

ANTIVIRAL AGENTS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; NEOPLASMS; RISK FACTORS; VIRUS ACTIVATION;

EID: 84953332834     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-2722     Document Type: Editorial

References (10)

1. Lok AS, Ward JW, Perrillo RP, McMahon BJ, Liang TJ. Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Ann Intern Med. 2012;156:743-5. [PMID: 22586011].
2. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008; 148:519-28. [PMID: 18378948].
3. Dong HJ, Ni LN, Sheng GF, Song HL, Xu JZ, Ling Y. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis. J Clin Virol. 2013;57:209-14. [PMID: 23562041].
4. Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology. 2015;61:703-11. [PMID: 25412906].
5. Perrillo RP, Martin P, Lok AS. Preventing hepatitis B reactivation due to immunosuppressive drug treatments. JAMA. 2015;313: 1617-8. [PMID: 25790287].
6. Artz AS, Somerfield MR, Feld JJ, Giusti AF, Kramer BS, Sabichi AL, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol. 2010;28:3199-202. [PMID: 20516452].
7. Day FL, Link E, Thursky K, Rischin D. Current hepatitis B screening practices and clinical experience of reactivation in patients undergoing chemotherapy for solid tumors: a nationwide survey of medical oncologists. J Oncol Pract. 2011;7:141-7. [PMID: 21886492].
8. Paul S, Saxena A, Terrin N, Viveiros K, Blak EM, Wong JB. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy. A systematic review and meta-analysis. Ann Intern Med. 2016;164:30-40. doi:10.7326/M15-1121.
9. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:221-244.e3. [PMID: 25447852].
10. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT; American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:215-9; quiz e16-7. [PMID: 25447850]. doi:10.1053/j.gastro.2014.10.039.